J. Goldman & CO LP Sarepta Therapeutics, Inc. Transaction History

J. Goldman & CO LP

$3.53 Billion
Q4 2024

A detailed history of J. Goldman & CO LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 87,866 shares of SRPT stock, worth $9.4 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

87,866

Previous 99,238 11.46%

Holding current value

$9.4 Million

Previous $12.4 Million 13.81%

% of portfolio

0.3%

Previous 0.39%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$104.54 - $137.94 $1.19 Million - $1.57 Million	-11,372 Reduced 11.46%	87,866 $10.7 Million
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $6.91 Million - $8.71 Million	55,585 Added 127.33%	99,238 $12.4 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $4.95 Million - $7.15 Million	43,653 New	43,653 $6.9 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $188,860 - $279,012	1,775 New	1,775 $203,000
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $5.43 Million - $9.62 Million	-70,947 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $1.98 Million - $4.26 Million	27,180 Added 62.1%	70,947 $5.34 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $1.25 Million - $1.9 Million	-23,124 Reduced 34.57%	43,767 $3.24 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $1.79 Million - $2.14 Million	-37,632 Reduced 36.0%	66,891 $3.72 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $3.73 Million - $4.93 Million	104,523	104,523 $4.74 Million

Others Institutions Holding SRPT

# of Institutions

536

Shares Held

87.4M

Call Options Held

1.55M

Put Options Held

1.35M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.37B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account